Commit
This commit does not belong to any branch on this repository, and may belong to a fork outside of the repository.
Merge pull request #542 from johnjaylward/fixXmlHexEntityParse
Fix xml hex entity parse
- Loading branch information
Showing
5 changed files
with
423 additions
and
11 deletions.
There are no files selected for viewing
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| Original file line number | Diff line number | Diff line change |
|---|---|---|
| @@ -0,0 +1,189 @@ | ||
| { | ||
| "clinical_study": { | ||
| "brief_summary": { | ||
| "textblock": "CLEAR SYNERGY is an international multi center 2x2 randomized placebo controlled trial of" | ||
| }, | ||
| "brief_title": "CLEAR SYNERGY Neutrophil Substudy", | ||
| "overall_status": "Recruiting", | ||
| "eligibility": { | ||
| "study_pop": { | ||
| "textblock": "Patients who are randomized to the drug RCT portion of the CLEAR SYNERGY (OASIS 9) trial" | ||
| }, | ||
| "minimum_age": "19 Years", | ||
| "sampling_method": "Non-Probability Sample", | ||
| "gender": "All", | ||
| "criteria": { | ||
| "textblock": "Inclusion Criteria:" | ||
| }, | ||
| "healthy_volunteers": "No", | ||
| "maximum_age": "110 Years" | ||
| }, | ||
| "number_of_groups": "2", | ||
| "source": "NYU Langone Health", | ||
| "location_countries": { | ||
| "country": "United States" | ||
| }, | ||
| "study_design_info": { | ||
| "time_perspective": "Prospective", | ||
| "observational_model": "Other" | ||
| }, | ||
| "last_update_submitted_qc": "September 10, 2019", | ||
| "intervention_browse": { | ||
| "mesh_term": "Colchicine" | ||
| }, | ||
| "official_title": "Studies on the Effects of Colchicine on Neutrophil Biology in Acute Myocardial Infarction: A Substudy of the CLEAR SYNERGY (OASIS 9) Trial", | ||
| "primary_completion_date": { | ||
| "type": "Anticipated", | ||
| "content": "February 1, 2021" | ||
| }, | ||
| "sponsors": { | ||
| "lead_sponsor": { | ||
| "agency_class": "Other", | ||
| "agency": "NYU Langone Health" | ||
| }, | ||
| "collaborator": [ | ||
| { | ||
| "agency_class": "Other", | ||
| "agency": "Population Health Research Institute" | ||
| }, | ||
| { | ||
| "agency_class": "NIH", | ||
| "agency": "National Heart, Lung, and Blood Institute (NHLBI)" | ||
| } | ||
| ] | ||
| }, | ||
| "overall_official": { | ||
| "role": "Principal Investigator", | ||
| "affiliation": "NYU School of Medicine", | ||
| "last_name": "Binita Shah, MD" | ||
| }, | ||
| "overall_contact_backup": { | ||
| "last_name": "Binita Shah, MD" | ||
| }, | ||
| "condition_browse": { | ||
| "mesh_term": [ | ||
| "Myocardial Infarction", | ||
| "ST Elevation Myocardial Infarction", | ||
| "Infarction" | ||
| ] | ||
| }, | ||
| "overall_contact": { | ||
| "phone": "646-501-9648", | ||
| "last_name": "Fatmira Curovic", | ||
| "email": "fatmira.curovic@nyumc.org" | ||
| }, | ||
| "responsible_party": { | ||
| "responsible_party_type": "Principal Investigator", | ||
| "investigator_title": "Assistant Professor of Medicine", | ||
| "investigator_full_name": "Binita Shah", | ||
| "investigator_affiliation": "NYU Langone Health" | ||
| }, | ||
| "study_first_submitted_qc": "March 12, 2019", | ||
| "start_date": { | ||
| "type": "Actual", | ||
| "content": "March 4, 2019" | ||
| }, | ||
| "has_expanded_access": "No", | ||
| "study_first_posted": { | ||
| "type": "Actual", | ||
| "content": "March 14, 2019" | ||
| }, | ||
| "arm_group": [ | ||
| { | ||
| "arm_group_label": "Colchicine" | ||
| }, | ||
| { | ||
| "arm_group_label": "Placebo" | ||
| } | ||
| ], | ||
| "primary_outcome": { | ||
| "measure": "soluble L-selectin", | ||
| "time_frame": "between baseline and 3 months", | ||
| "description": "Change in soluble L-selectin between baseline and 3 mo after STEMI in the placebo vs. colchicine groups." | ||
| }, | ||
| "secondary_outcome": [ | ||
| { | ||
| "measure": "Other soluble markers of neutrophil activity", | ||
| "time_frame": "between baseline and 3 months", | ||
| "description": "Other markers of neutrophil activity will be evaluated at baseline and 3 months after STEMI (myeloperoxidase, matrix metalloproteinase-9, neutrophil gelatinase-associated lipocalin, neutrophil elastase, intercellular/vascular cellular adhesion molecules)" | ||
| }, | ||
| { | ||
| "measure": "Markers of systemic inflammation", | ||
| "time_frame": "between baseline and 3 months", | ||
| "description": "Markers of systemic inflammation will be evaluated at baseline and 3 months after STEMI (high sensitive CRP, IL-1β)" | ||
| }, | ||
| { | ||
| "measure": "Neutrophil-driven responses that may further propagate injury", | ||
| "time_frame": "between baseline and 3 months", | ||
| "description": "Neutrophil-driven responses that may further propagate injury will be evaluated at baseline and 3 months after STEMI (neutrophil extracellular traps, neutrophil-derived microparticles)" | ||
| } | ||
| ], | ||
| "oversight_info": { | ||
| "is_fda_regulated_drug": "No", | ||
| "is_fda_regulated_device": "No", | ||
| "has_dmc": "No" | ||
| }, | ||
| "last_update_posted": { | ||
| "type": "Actual", | ||
| "content": "September 12, 2019" | ||
| }, | ||
| "id_info": { | ||
| "nct_id": "NCT03874338", | ||
| "org_study_id": "18-01323", | ||
| "secondary_id": "1R01HL146206" | ||
| }, | ||
| "enrollment": { | ||
| "type": "Anticipated", | ||
| "content": "670" | ||
| }, | ||
| "study_first_submitted": "March 12, 2019", | ||
| "condition": [ | ||
| "Neutrophils.Hypersegmented | Bld-Ser-Plas", | ||
| "STEMI - ST Elevation Myocardial Infarction" | ||
| ], | ||
| "study_type": "Observational", | ||
| "required_header": { | ||
| "download_date": "ClinicalTrials.gov processed this data on July 19, 2020", | ||
| "link_text": "Link to the current ClinicalTrials.gov record.", | ||
| "url": "https://clinicaltrials.gov/show/NCT03874338" | ||
| }, | ||
| "last_update_submitted": "September 10, 2019", | ||
| "completion_date": { | ||
| "type": "Anticipated", | ||
| "content": "February 1, 2022" | ||
| }, | ||
| "location": { | ||
| "contact": { | ||
| "phone": "646-501-9648", | ||
| "last_name": "Fatmira Curovic", | ||
| "email": "fatmira.curovic@nyumc.org" | ||
| }, | ||
| "facility": { | ||
| "address": { | ||
| "zip": "10016", | ||
| "country": "United States", | ||
| "city": "New York", | ||
| "state": "New York" | ||
| }, | ||
| "name": "NYU School of Medicine" | ||
| }, | ||
| "status": "Recruiting", | ||
| "contact_backup": { | ||
| "last_name": "Binita Shah, MD" | ||
| } | ||
| }, | ||
| "intervention": { | ||
| "intervention_type": "Drug", | ||
| "arm_group_label": [ | ||
| "Colchicine", | ||
| "Placebo" | ||
| ], | ||
| "description": "Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.", | ||
| "intervention_name": "Colchicine Pill" | ||
| }, | ||
| "patient_data": { | ||
| "sharing_ipd": "No" | ||
| }, | ||
| "verification_date": "September 2019" | ||
| } | ||
| } |
Oops, something went wrong.